Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Utilization Patterns of Pulmicort in Real Life Practice

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: April 15, 2008
Last updated: November 30, 2010
Last verified: November 2010
The purpose of this study is to identify the potential issues during short and mid term utilization of Pulmicort hydro fluoroaklane (HFA) pressurized metered-dose inhaler (pMDI)and describe associated factors.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Utilization Patterns of Pulmicort HFA in Real Life Practice

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Enrollment: 260
Study Start Date: January 2008
Study Completion Date: February 2009
Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Population treated by General Practitioner, Pneumologists or Paediatricians

Inclusion Criteria:

  • Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion
  • Patients previously treated with Pulmicort CFC who have changed their treatment to Pulmicort HFA

Exclusion Criteria:

  • Disability that, from investigator point of view, prevent from complying the follow up schedule
  • To have participated in any clinical study in the past 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00660569

Research Site
Sabadell, Barcelona, Spain
Research Site
Alcorcon, Madrid, Spain
Research Site
Leganes, Madrid, Spain
Research Site
San Sebastian de los Reyes, Madrid, Spain
Research Site
Olivares, Sevilla, Spain
Research Site
Fuentes de Ebro, Zaragoza, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Murcia, Spain
Research Site
Toledo, Spain
Sponsors and Collaborators
Study Director: Javier Nuevo Rivero AstraZeneca MC SpainEpidemiologyValue Demonstration Unit
  More Information

Responsible Party: Mónica Tafalla/Medical Science Director, AstraZeneca Identifier: NCT00660569     History of Changes
Other Study ID Numbers: NIS-RES-PUL-2007/1 
Study First Received: April 15, 2008
Last Updated: November 30, 2010
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by AstraZeneca:
asthma treatment
real life practice

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on October 21, 2016